Literature DB >> 26742698

An update on multipurpose prevention technologies for the prevention of HIV transmission and pregnancy.

David R Friend1.   

Abstract

INTRODUCTION: Multipurpose Prevention Technologies (MPTs) are designed to address two or more indications from a single product. The overall goal is to prevent unintended pregnancy and transmission of one or more STIs including HIV-1. AREAS COVERED: The topics covered herein are advances in over the past three years. Advances include development of novel intravaginal rings capable of releasing microbicides to prevent transmission of HIV-1 and unintended pregnancy. These rings include the potential to prevent transmission of more than one STI and unintended pregnancy. There are also gels that can potentially accomplish the same thing. Finally, combination of a drug and barrier device are also covered. EXPERT OPINION: There has been considerable advance in this field over the past three years. There is one ring currently in a Phase I clinical trial and others are soon to follow. Some of these drug delivery systems are by necessity rather complicated and hence could be prohibitively expensive in the developing world. Conducting multiple clinical trials to support regulatory approval of two or more indications represents a significant barrier. It remains unclear that women will be more motivated to use MPT products than has been observed in recent microbicide-only clinical trials. Despite these challenges, the need for MPTs remain acute hopefully ensuring they will continue to be developed over the coming years.

Entities:  

Keywords:  Contraception; HIV-1 prevention; STI prevention; intravaginal rings; multipurpose prevention technologies; vaginal gels

Mesh:

Substances:

Year:  2016        PMID: 26742698     DOI: 10.1517/17425247.2016.1134485

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  11 in total

1.  Preferred Product Attributes of Potential Multipurpose Prevention Technologies for Unintended Pregnancy and Sexually Transmitted Infections or HIV Among U.S. Women.

Authors:  Jenna S Hynes; Anandi N Sheth; Eva Lathrop; Jessica M Sales; Lisa B Haddad
Journal:  J Womens Health (Larchmt)       Date:  2019-01-04       Impact factor: 2.681

2.  Residual hormone levels in used contraceptive rings as a measurement of adherence to vaginal ring use.

Authors:  Richard E Haaland; Angela Holder; Tammy Evans-Strickfaden; Beatrice Nyagol; Mumbi Makanga; Boaz Oyaro; Felix Humwa; Tiffany Williams; Eleanor McLellan-Lemal; Mitesh Desai; Michael J Huey
Journal:  Contraception       Date:  2017-04-01       Impact factor: 3.375

3.  Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?

Authors:  Chelsea B Polis; Sharon J Phillips; Sharon L Hillier; Sharon L Achilles
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

4.  Interest in multipurpose prevention technologies to prevent HIV/STIs and unintended pregnancy among young women in the United States.

Authors:  Jenna S Hynes; Jessica M Sales; Anandi N Sheth; Eva Lathrop; Lisa B Haddad
Journal:  Contraception       Date:  2017-10-18       Impact factor: 3.375

5.  Hormonal Contraceptives Differentially Suppress TFV and TAF Inhibition of HIV Infection and TFV-DP in Blood and Genital Tract CD4+ T cells.

Authors:  Zheng Shen; Marta Rodriguez-Garcia; Mickey V Patel; Jack Bodwell; Angela D M Kashuba; Charles R Wira
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

6.  The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa.

Authors:  Matthew Quaife; Fern Terris-Prestholt; Robyn Eakle; Maria A Cabrera Escobar; Maggie Kilbourne-Brook; Mercy Mvundura; Gesine Meyer-Rath; Sinead Delany-Moretlwe; Peter Vickerman
Journal:  J Int AIDS Soc       Date:  2018-03       Impact factor: 5.396

7.  Rhodanine derivatives as potent anti-HIV and anti-HSV microbicides.

Authors:  Cristina Tintori; Giulia Iovenitti; Elisa Rita Ceresola; Roberto Ferrarese; Claudio Zamperini; Annalaura Brai; Giulio Poli; Elena Dreassi; Valeria Cagno; David Lembo; Filippo Canducci; Maurizio Botta
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

8.  Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.

Authors:  Kathleen L Vincent; John A Moss; Mark A Marzinke; Craig W Hendrix; Peter A Anton; Richard B Pyles; Kate M Guthrie; Lauren Dawson; Trevelyn J Olive; Irina Butkyavichene; Scott A Churchman; John M Cortez; Rob Fanter; Manjula Gunawardana; Christine S Miller; Flora Yang; Rochelle K Rosen; Sara E Vargas; Marc M Baum
Journal:  PLoS Med       Date:  2018-09-28       Impact factor: 11.069

9.  Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.

Authors:  James M Smith; John A Moss; Priya Srinivasan; Irina Butkyavichene; Manjula Gunawardana; Rob Fanter; Christine S Miller; Debbie Sanchez; Flora Yang; Shanon Ellis; Jining Zhang; Mark A Marzinke; Craig W Hendrix; Amita Kapoor; Marc M Baum
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

Review 10.  In Vitro Methods for Evaluating Drug Release of Vaginal Ring Formulations-A Critical Review.

Authors:  Katharina Tietz; Sandra Klein
Journal:  Pharmaceutics       Date:  2019-10-16       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.